Compare CNXN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNXN | RAPP |
|---|---|---|
| Founded | 1982 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1997 | 2024 |
| Metric | CNXN | RAPP |
|---|---|---|
| Price | $70.14 | $38.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | 139.6K | ★ 291.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $104.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.97 | $11.05 |
| 52 Week High | $75.00 | $42.27 |
| Indicator | CNXN | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 55.84 |
| Support Level | $56.30 | $33.54 |
| Resistance Level | $75.00 | $40.61 |
| Average True Range (ATR) | 2.14 | 2.49 |
| MACD | -0.40 | 0.18 |
| Stochastic Oscillator | 30.49 | 65.25 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.